Kailera Therapeutics
Kailera Therapeutics develops oral and injectable medicines for obesity using several GLP-1-based mechanisms.
$600MSeries B
ParticipantSC
Surveyor Capital
Activity from announced rounds
Activity in this selectionHealthtech
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $600M 1 disclosed · full round size, not this investor’s share